Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Baylor College of Medicine
Eastern Cooperative Oncology Group
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Haihe Biopharma Co., Ltd.
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Adela, Inc
M.D. Anderson Cancer Center